// you’re reading...

General Biotechnology

Biotech industry seeks control of its destiny

Biotech industry seeks control of its destiny
Human Genome Sciences and a small but determined group of its peers are charting unconventional territory. Their efforts to take over the production, sales and marketing of selected portions of their portfolios signals a potential turning point in the industry. The companies contend that they can and should own more of the process that delivers biotechnology’s molecules to market - a process now firmly in the control of the pharmaceutical industry.

Discussion

No comments for “Biotech industry seeks control of its destiny”

Post a comment